Click here to listen to Dr. Kay’s interview.
The next time Dr. Kay attends a lecture, someone in the room may be his next subject. He typically makes several sketches of the person, drawing simple lines on a napkin or notepad before he achieves an image that really conveys the true essence of that individual.
There may be no higher form of flattery.
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition
Like solving sudoku, planning the ACR annual meeting requires an ability to recognize patterns and employ focused logical thinking, all the while remaining undaunted by the various paths possible to complete a grid from what looks like, at initial glance, an incomprehensible labyrinth of options. The patterns in this situation are not numbers, but sessions,…
Rheumatologists who are outstanding clinicians, providing consistently exceptional care to patients and serving as role models for colleagues and trainees, are highlighted in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Jonathan Kay, MD, is professor of medicine,…